MedCity News December 26, 2024
Frank Vinluan

Corxel Pharmaceuticals has acquired an oral small molecule GLP-1 agonist with potential applications in obesity and diabetes. The Phase 2-ready pill could compete with oral metabolic meds in development by companies such as Roche, AstraZeneca, and Structure Therapeutics.

Obesity drugs that offer the benefits of currently available injectable drugs, but in pill form, are part of the next wave of metabolic medicines in development. Cardiometabolic disease biotech Corxel Pharmaceuticals is getting a contender in a deal that brings a Phase 2-ready drug candidate.

Corxel announced this week the acquisition of VCT220, a small molecule GLP-1 agonist developed by China-based Vincentage Pharma. Privately held Corxel, which is based in Shanghai and maintains U.S. operations in New Jersey, gains global rights to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma / Biotech
Related Articles:
Gene Therapy for Cardiomyopathies Presents Promising Alternative to Current Treatment
STAT+: 3 trends to watch in biotech in 2025
The GLP-1 dilemma persists into 2025
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs

Share This Article